Announced merger agreement with Eos SENOLYTIX in March
Series B Preferred Stock investment made in Pulmatrix with a conversion price of $2.20 is a part of the ongoing merger process
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that could limit superior...
FRAMINGHAM, Mass. and HOUSTON , March 26, 2026 /PRNewswire/ -- Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix") and Eos SENOLYTIX, Inc. ("Eos"), a biotechnology company developing novel gerotherapeutic...
Cullgen had been seeking approval for a merger with Pulmatrix from the China Securities Regulatory Commission and on February 28, 2026, notified Pulmatrix that Cullgen was terminating the Merger Agreement...
Plans to License or Monetize our Migraine and Inhalation Assets Continue
Pulmatrix continues to support Cullgen in seeking approval for their merger from the China Securities Regulatory Commission
As part of the proposed merger, Pulmatrix currently intends to divest its assets including its proprietary dry powder delivery technology, iSPERSE™, which enables delivery of small- or large-molecule...
Proposed merger anticipated to close in 2025
/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...